The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Using molecular features to determine appropriate treatment strategies for patients with CLL
In this video, Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, highlights the importance of identifying molecular features of patients with chronic lymphocytic leukemia (CLL) to better understand how they may respond to therapeutic agents, and comments on the value of creating genomic databases containing this information. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
MEI Pharma: Consultancy; Fate Therapeutics: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; TG Therapeutics: Consultancy, Research Funding; Innate Pharma: Consultancy; Epi Lilly: Consultancy; Adaptimmune: Consultancy; AstraZeneca: Consultancy, Research Funding; Epizyme: Consultancy; Mustang Bio: Consultancy, Research Funding; Beigene: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Regeneron: Consultancy; Merck: Consultancy; Adaptive Biotechnologies: Consultancy; Morphosys/Incyte: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Sound Biologics: Consultancy; Kite Pharma: Consultancy; Abbvie: Consultancy, Research Funding; Atara Biotherapeutic: Consultancy, Research Funding; Celgene, a BMS Company: Research Funding; Gilead: Research Funding; Sunesis: Research Funding; Genmab: Research Funding.
